FDA Approves Treosulfan with Fludarabine As a Preparative Regimen for alloHSCT in Adult and Paediatric Patients with AML or MDS By Ogkologos - March 13, 2025 764 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MC-FludT.14/L Trial II Source RELATED ARTICLESMORE FROM AUTHOR Adding Relacorilant to Nab-paclitaxel Prolongs OS in Patients with Platinum-Resistant Ovarian Cancer Quadruplet Isa-KRd Regimen Improves NGS-MRD Negativity in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma EMA Recommends Granting a Marketing Authorisation for Tarlatamab MOST POPULAR Michelle Mitchell: Cancer is a fixable problem May 23, 2023 FDA Approves Margetuximab for Metastatic HER2-positive Breast Cancer January 4, 2021 Patient Guide in Prostate Cancer Now Available Also in German December 18, 2025 ESMO Welcomes New Cancer Focused UN Political Declaration on Non-Communicable Diseases October 6, 2025 Load more HOT NEWS Lymph Node Biopsies Are Unnecessary For Early-Stage Breast Cancer Patients, Study... Copanlisib Shows Promising Clinical Activity in Select Tumours with PIK3CA Mutation... Preliminary Evidence of Efficacy of an Upfront ICI-based Therapeutic Strategy in... Suggesting a Deadline in the Invitation Letter to FIT Colorectal Cancer...
